Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Walmsley: GSK Is 'Prepared' And 'Ready' For US Advair Generic Launch

Executive Summary

GlaxoSmithKline is poised for a challenging 2018, with an interchangeable Advair generic expected to launch, but GSK believes growth from new products will make up some of the loss. US Advair sales could be slashed to £750m from £1.6bn in 2017.

Advertisement

Related Content

Three Strikes For Generic Advair With An FDA CRL For Sandoz
GSK Rides Cold, Flu And Pain OTCs In Q4 While Allergy Carries Sanofi
Cipla Evaluates US Portfolio Tucks, Generic Advair Studies Progress
Pfizer Mum On Consumer Business Plans As Analysts Say Spin-off
FDA's NDA And BLA Approvals: Xhance, Trelegy Ellipta, Clorotekal, Verzenio
Hikma's CRL Proves GSK's Witty Was Right: Generic Advair Is Hard
GSK Braces For Impact: Advair Generic Could Reduce US Brand To £1Bn
GSK To Launch Mepolizumab For Severe Asthma By Year-End
GSK Set For Breo Launch, But Access Will Require Time

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100357

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel